Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Echo starts new study of noninvasive glucose monitor

This article was originally published in Clinica

Executive Summary

Echo Therapeutics has started another pilot study of its noninvasive wireless Symphony transdermal continuous glucose monitoring system (tCGM). Results from the study, in 10 type 1 and type 2 diabetes patients, are expected in the third quarter of 2008. The primary purpose of the trial is to evaluate the Symphony system with the Franklin, Massachusetts firm's new Prelude skin preparation system. It will compare data obtained using Symphony with the gold-standard YSI (Yellow Springs Instrument) Glucose Analyzer and a widely-used "finger stick" glucometer. Echo is developing Symphony for use both at home and in hospital. In March, it reported encouraging results from another pilot study (see Clinica No 1299, p 26). Other noninvasive glucose tests include OrSense's ring-like monitor, NBM-200G, and GlucoLight's Sentris-100.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel